Navigation Links
Zertane™ Clinical Results Published in the Journal European Urology
Date:8/30/2011

GREENWOOD VILLAGE, Colo., Aug. 30, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that the manuscript reporting the results of its phase III clinical trials of Zertane™ for the treatment of the sexual dysfunction, premature ejaculation (PE), was accepted for publication in European Urology.

Scientific Journal

European Urology has the highest impact factor in the world in the field of urology and is currently read by more than 20,000 urologists across the globe. With an impact factor of 8.843, the journal has become the leading scientific publication in the field http://www.europeanurology.com. Impact factor, a measure reflecting the average number of citations to articles published in science journals, is frequently used as a proxy for the relative importance of a journal within its field.  Journals with higher impact factors are deemed to be more important than those with lower ones (Wikipedia).

Manuscript

The manuscript entitled: "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Orally Disintegrating Tablet for the Treatment of Premature Ejaculation Less than 2 Minutes" authored by Dr. David Bar-Or, MD, the Chief Scientific officer and his colleagues at Ampio Pharmaceuticals, Inc., details the successful efficacy and safety outcomes of the use of Zertane™ in double blinded, placebo controlled phase III trials involving 604 intent to treat patients in 11 countries and 62 sites in Europe. A brief summary of the findings are as follows:

  • Premature ejaculation (PE) is a widely observed male sexual dysfunction with an estimated prevalence between 2% and 23% of the world male population.
  • Studies have shown that PE is associated with poor satisfaction with sexual intercourse and high levels of ejaculation-related personal distress and interpersonal difficulty.
  • The median IELT (intravaginal ejaculatory latency time) with the 62mg dosage of Zertane™ increased by 2.4 fold compared to placebo (p<0.001).
  • All four measures of the PEP (Premature Ejaculation Profile, a validated questionnaire) scores improved significantly compared to placebo (p<0.05) in men.  Further, a large percentage of women partners who had poor or very poor satisfaction with their sexual intercourse partner's control over ejaculation and speed of ejaculation reported significantly improved satisfaction with 62mg Zertane™ in at least one category:  sexual intercourse (p=0.01), their partner's control over ejaculation (p<0.001) and distress over partner's speed of ejaculation (p=0.02).
  • The study concludes that on demand Zertane™ provides a new option for managing mild to severe PE and that at the 62 mg very favorable efficacy and safety profiles exist.
  • The full publication ahead of print appears online in European Urology  (http://www.europeanurology.com/articles-in-press)

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, such as changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact:
Investor Relations
Ampio Pharmaceuticals, Inc.
720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... diagnostic tests and pathology services for evaluating risks of ... dated January 13, 2017 from the NASDAQ Listing Qualifications ... the requirement of the NASDAQ Stock Market to maintain ... The letter noted that for the last ...
(Date:1/17/2017)... and Markets has announced the addition of the "The Top 200 ... ... profiles the leading 200 manufacturers and distributors of molecular diagnostics products worldwide. ... States and Europe to ... Profile information for each company in The Top 200 Molecular Diagnostics Companies ...
(Date:1/17/2017)... Catherine Amey ; ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Neurological Review , the ... reports that despite standard care, temperatures exceeding 37.5°C ...
Breaking Medicine Technology:
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ... Athletic Training Education program forged a relationship built upon the foundation of sports ... is consists of both student members and certified members of the Athletic Trainers’ ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. ... CalSouthern’s Board of Trustees and as a core faculty member, teaching master’s and doctoral ... professor of psychology at Pepperdine University, where he earned his Doctor of Psychology degree ...
(Date:1/16/2017)... ... 2017 , ... With the Grand Opening Event planned for February 3, 2017, ... teams and the general public. Built in five months by Centerpoint, the 60,000 square ... basketball or pickleball courts. The space is also suitable for indoor soccer and football ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... announced the addition of Victor Giamos, MD to their medical staff, according to ... Partner at North Shore Eye Care, a division of SightMD. Dr. Giamos will ...
Breaking Medicine News(10 mins):